John Havlik, MD, MBA
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California
Original Research
Innovation in Psychiatric Drug Development: A Quantitative Analysis of FDA-Approved Psychiatric Drugs, 2012–2024
January 12, 2026
Innovation in psychiatric drug development in the past 13 years was limited, with most new drugs representing incremental advances rather than groundbreaking innovations.
